Oncology
Overview
Invicro uniquely combines operational excellence with extensive scientific and medical expertise. Our goal is to drive the advancement of translational cancer research, aid in cancer drug development and develop imaging methods and tools that enable precision medicine. We have experience working with a wide range of therapeutics, including small molecules, peptides, antibodies, multi-specific proteins, CAR-T cells, and many more. Preclinically and clinically, Invicro offers a wide variety of oncology biomarker solutions, including:
- Central imaging core lab for Phase 0-IV clinical studies
- Preclinical/Clinical novel molecular imaging tracers
- In vitro, in vivo, and ex vivo techniques in rodents through NHPs
- Autoradiography, histology and quantitative immunohistochemistry
- Qualitative and quantitative image analytics
Invicros radiochemistry team has experience with almost all commercially available radioisotopes used for PET/SPECT imaging and several used in targeted radiotherapy. Our capabilities span from first-in-human clinical studies to GMP implementation of novel radiotracers, including:
- A Microdose PET Study of the Safety, Immunogenicity, Biodistribution, and Radiation Dosimetry of 18F-FB-A20FMDV2 for Imaging the Integrin αvβ
- Clinical Translation of a Click-Labeled 18F-Octreotate Radioligand for Imaging Neuroendocrine Tumors
- 18F-ICMT-11, a Caspase-3–Specific PET Tracer for Apoptosis: Biodistribution and Radiation Dosimetry
- Biodistribution and radiation dosimetry of deuterium-substituted 18F-fluoromethyl-[1, 2-2H4]choline in healthy volunteer
We have experience with multiple rodent models and the flexibility to either produce models in-house or receive them from outside vendors or collaborators. Common models include:
- Syngeneic models
- Human xenograft tumors in immunocompromised mice
- Humanized mouse models
- GEMM mouse model
We also work with larger species including canine, porcine, and non-human primates (NHP).
Invicro has a central imaging core lab, including study design, site set-up and training, development of imaging protocol, expert blinded reads and full 21 CFR Part 11 compliance. We have qualitative and advanced quantitative analysis techniques, including:
- Segmentation
- Image co-registration
- Radiation dosimetry
- Mechanistic pharmacokinetic modeling including PBPK modeling
- Tracer kinetic modeling
- Radiomics
- Imaged-based machine learning
- Full service independent blind reads or collect and hold capabilities
- Response criteria – RANO, Lugano, PCWG, IMWG, RECIST, Cheson, iRECIST, irRECIST, irRC and LYRIC
Invicro also brings experience in PET bio-distribution studies using radiolabeled anti-cancer agents.
- Focal adhesion kinase inhibitor GSK2256098 (Neuro Oncol. 2018 May 17)
- Lapatinib (EJNMMI Res. 2015 Apr 30;5:30)
- PET
- SPECT
- CT
- MR
- US
- Bioluminescence
- Fluorescence Molecular Tomography (FMT)
- Cryo-fluorescence tomography (CFT)
- ex vivo fluorescence reflectance imaging
- Autoradiography & micro-autoradiography
- Histology, immunohistochemistry, and quantitative immunohistochemistry
- Gamma counting
- Flow cytometry
- Clinical chemistry
- CBC analysis
- Urinalysis
- Tissue homogenate binding
- Cell culture
- Cell binding and competition
- Internalization
- ELISA
- Western blots
- Targeted radiotherapeutics